From: Systematic review of melanoma incidence and prognosis in solid organ transplant recipients
First author (publication year) | Location | Transplant data source | Number of cases of melanoma | Staging data (number of patients with data) | Outcomes |
---|---|---|---|---|---|
Brewer[20]a | United States | Mayo Clinic databases, OPTN, IPITTR | 638 | AJCC pathologic stage (67 tumors) | Worse 3-year, cause-specific survival for Breslow 1.51 to 3.0Â mm and Clark level III or IV in transplant recipients versus controls. |
 |  |  |  | Breslow depth (123) |  |
Frankenthaler[21] | United States | BIDMC Cutaneous Oncology Program database | 4 (renal transplant) 15 (autoimmune disease) | AJCC stage (19) | Similar relapse rates but worse overall survival in immunosuppressed group versus controls. |
 |  |  |  |  | Similar stage distribution at diagnosis compared to general melanoma database. |
Matin[26] | Europe | SCOPE, AJCC | 89 | Breslow depth (83) | Worse overall survival for Breslow >2 mm in transplant patients versus controls (HR 11.5, 95% CI 3.6 to 36.8), but not found for Breslow ≤2 mm (HR 1.5, 95% CI 0.31 to 6.9). |
Clark level (82) | |||||
Ulceration (79) | |||||
 |  |  |  |  | 14 patients with metastasis. |
Le Mire[22] | United Kingdom | Oxford renal transplant unit | 10 | Breslow depth (10) Clark level (10) Ulceration (10) | 1 patient died from metastatic melanoma (Breslow 4.5Â mm). |
 |  |  |  |  | No recurrence in other cases (all <1 mm). |
Veness[23] | Australia | St Vincent Hospital, Sydney | 8 | Regional lymph node status (2) | 4 deaths from metastasis. |
Lévêque[24] | France | 9 centers | 17 | Breslow depth (16) Clark level (16) Ulceration (16) | 4 deaths from metastasis |